Shares of SRF Limited jumped sharply in early trade on Wednesday, rising 6.47 per cent to ₹2,685.90 on the NSE by 11.07 am, a day after the specialty chemicals conglomerate posted better-than-expected results for the fourth quarter and full year ended March 2026. The stock opened at ₹2,605, touched a high of ₹2,693.60, and was trading with a buy-heavy order book — 56.16 per cent buy versus 43.84 per cent sell — with traded value already crossing ₹494 crore by mid-morning.
The strong price action comes after SRF’s Q4FY26 results, released on Tuesday, showed consolidated revenue of ₹4,615 crore, up 7 per cent year-on-year, with EBITDA margins expanding 180 basis points to 25 per cent against analyst estimates of 23 per cent. Adjusted PAT grew 20 per cent year-on-year to ₹690 crore. For the full year FY26, revenue, EBITDA, and adjusted PAT grew 7 per cent, 27 per cent, and 51 per cent respectively.
Motilal Oswal Financial Services maintained a Buy rating on the stock with a current market price of ₹2,528 — now well below the trading price — noting that operating performance beat estimates across segments, led by the Chemicals business which reported EBIT margins of 32 per cent.
SBI Securities flagged two key capital allocation developments as neutral to positive in the short to medium term. The board has indefinitely deferred the ₹490 crore BOPP film manufacturing facility at Indore, citing a reassessment of investment timing. Simultaneously, the refrigerants project capex in Odisha has been revised upward significantly — from ₹1,100 crore to ₹2,285 crore — now covering a 20,000 MTPA HFO facility, a 30,000 MTPA new HF plant, and value-added HF derivatives, with completion targeted by February 2028.
The stock is currently trading well below its 52-week high of ₹3,325 hit in July 2025, and not far from its 52-week low of ₹2,355 touched in April 2026, giving it room to recover as investor sentiment improves on the back of margin expansion and strategic capex clarity.
Published on May 6, 2026